Connor Iapoce

The FDA Circulatory System Devices Panel has voted in favor of the benefit-risk profile of Recor Medical's RDN system in a 10-2 vote but declined to endorse Medtronic's system in a 6-7 vote.

Presented at ESC 2023, the accumulation of inactive time from childhood through young adulthood was related to heart damage, regardless of body weight and blood pressure.

Across 31 centers in England, hybrid closed-loop therapy was associated with improvements in HbA1c, sensor glucometrics, and diabetes-related distress in adults with T1D.

Apellis Pharmaceuticals identified internal structural variations in the 19-gauge filter needle included in certain injection kits for pegcetacoplan injection, the first FDA-approved treatment for geographic atrophy.

A new analysis suggests improved self-recognition of myocardial infarction symptoms may reduce cardiogenic shock and death by prompting a rapid hospital visit.

A study of more than 15,000 individuals suggests regular physical activity may help prevent the development of atrial fibrillation, as well as the incidence of stroke and MACE.

Early rapid weight gain after diagnosis of T1D may play a role in the lack of remission and shorter duration of partial remission, potentially due to altered insulin sensitivity.

The adjusted odds of vision testing decreased by 41% for uninsured and 24% for publicly insured participants versus those with private insurance.

Trends show e-cigarette use in patients with CVD decreased from 2015 to 2019, but rebounded in 2019, potentially owing to the COVID-19 pandemic.

Initial real-world experience with ranibizumab biosimilar agents revealed no unexpected adverse outcomes across 16 retina centers, with similar efficacy to reference ranibizumab.

Results from the CT-P42 3.1 Study indicate the therapeutic equivalence of the aflibercept biosimilar, CT-P42, to the reference product in eyes with DME.

In this episode, host Veeral Sheth, MD, and producer Connor Iapoce discuss 5 presentations from ASRS 2023. The discussion centered around new data on geographic atrophy therapies, novel agents for DME, and the feasibility of home OCT.

Real-world data show the benefits of DEX implants prior to cataract surgery to achieve sufficient postoperative inflammation management and limit deterioration.

A multi-center study in France found recreational drug use was independently associated with the occurrence of in-hospital outcomes.

Comparable efficacy, including of BCVA, CST, and fluid status between SB15 and reference aflibercept, was maintained up to Week 56 in nAMD eyes.

Health data from more than 50,000 adults revealed racial differences in cardiovascular mortality disappeared after adjusting for social risk factors.

Each month, our editorial staff compiles a recap of the top news in ophthalmology from the past month. Our July 2023 month-in-review features a recap of conference coverage from the ASRS 41st Annual Scientific Meeting.

A new analysis suggests pseudomyopia was an independent risk factor for myopia development among school-aged children in China.

Results from the real-world AUSSIEDEX study suggest dexamethasone implant significantly improved anatomic outcomes at 52 weeks and showed no new safety concerns.

Large learning model-based platforms provide largely inaccurate responses to questions concerning vitreoretinal disease and remain inconsistent on repeat queries.

New study data indicate the growing knowledge of artificial intelligence chatbots in ophthalmology. We are joined by 3 study investigators to discuss what this could mean for the field overall and its impact on patient care.

A single dose of intravitreal bevacizumab in individuals undergoing trabeculectomy for progressing glaucoma shows improved postoperative outcomes at 12 months.

New 96-week data from PULSAR show patients treated with aflibercept 8 mg achieved good durability and maintained visual acuity gains from year 1 through year 2 of study.

Anatomic and visual improvements with high-dose aflibercept in CANDELA indicate a potential therapeutic benefit over aflibercept 2 mg, despite not achieving statistical significance.

Results from FARETINA-DME indicate a majority of eyes with DME began extending treatment intervals after 1-2 initial doses of faricimab.

Positive topline results from the phase 3 trial suggest once-daily OCS-01 met both primary trial endpoints for the treatment of inflammation and pain following cataract surgery.

Last week, the FDA authorized marketing for Viz.AI’s Viz HCM, a standalone ECG analysis software to identify adult patients for further follow-up for hypertrophic cardiomyopathy.

Last week's FDA approval of avacincaptad pegol marked the second approved treatment for geographic atrophy in 2023. Here, 4 retina specialists discuss the complement inhibitor and what it could represent for patients with GA.

Data from PK profiles and safety analyses of intravitreal sozinibercept suggest the promise of the drug in combination with standard anti-VEGF agents for AMD and DME.

Presented at ASRS 2023, results from the phase 2 ZETA-1 trial showed oral APX3330 missed its primary endpoint, but the consideration of a binocular treatment effect may warrant further clinical development.